293 related articles for article (PubMed ID: 21948088)
1. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
Belyea BC; Naini S; Bentley RC; Linardic CM
Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088
[TBL] [Abstract][Full Text] [Related]
2. A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma.
Slemmons KK; Crose LES; Riedel S; Sushnitha M; Belyea B; Linardic CM
Mol Cancer Res; 2017 Dec; 15(12):1777-1791. PubMed ID: 28923841
[TBL] [Abstract][Full Text] [Related]
3. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
[TBL] [Abstract][Full Text] [Related]
4. RBPJ is a novel target for rhabdomyosarcoma therapy.
Nagao H; Setoguchi T; Kitamoto S; Ishidou Y; Nagano S; Yokouchi M; Abematsu M; Kawabata N; Maeda S; Yonezawa S; Komiya S
PLoS One; 2012; 7(7):e39268. PubMed ID: 22792167
[TBL] [Abstract][Full Text] [Related]
5. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R
Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430
[TBL] [Abstract][Full Text] [Related]
6. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
[TBL] [Abstract][Full Text] [Related]
7. Human myostatin negatively regulates human myoblast growth and differentiation.
McFarlane C; Hui GZ; Amanda WZ; Lau HY; Lokireddy S; Xiaojia G; Mouly V; Butler-Browne G; Gluckman PD; Sharma M; Kambadur R
Am J Physiol Cell Physiol; 2011 Jul; 301(1):C195-203. PubMed ID: 21508334
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of myogenesis by Notch: evidence for multiple pathways.
Buas MF; Kabak S; Kadesch T
J Cell Physiol; 2009 Jan; 218(1):84-93. PubMed ID: 18727102
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
[TBL] [Abstract][Full Text] [Related]
10. Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression.
Alaña L; Sesé M; Cánovas V; Punyal Y; Fernández Y; Abasolo I; de Torres I; Ruiz C; Espinosa L; Bigas A; Y Cajal SR; Fernández PL; Serras F; Corominas M; Thomson TM; Paciucci R
Mol Cancer; 2014 Mar; 13():74. PubMed ID: 24684754
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.
Raimondi L; Ciarapica R; De Salvo M; Verginelli F; Gueguen M; Martini C; De Sio L; Cortese G; Locatelli M; Dang TP; Carlesso N; Miele L; Stifani S; Limon I; Locatelli F; Rota R
Cell Death Differ; 2012 May; 19(5):871-81. PubMed ID: 22117196
[TBL] [Abstract][Full Text] [Related]
12. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
[TBL] [Abstract][Full Text] [Related]
13. MAML1 regulates cell viability via the NF-κB pathway in cervical cancer cell lines.
Kuncharin Y; Sangphech N; Kueanjinda P; Bhattarakosol P; Palaga T
Exp Cell Res; 2011 Aug; 317(13):1830-40. PubMed ID: 21640102
[TBL] [Abstract][Full Text] [Related]
14. Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice.
Singh S; Vinson C; Gurley CM; Nolen GT; Beggs ML; Nagarajan R; Wagner EF; Parham DM; Peterson CA
Am J Pathol; 2010 Oct; 177(4):2055-66. PubMed ID: 20829439
[TBL] [Abstract][Full Text] [Related]
15. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation.
Tanaka M; Setoguchi T; Hirotsu M; Gao H; Sasaki H; Matsunoshita Y; Komiya S
Br J Cancer; 2009 Jun; 100(12):1957-65. PubMed ID: 19455146
[TBL] [Abstract][Full Text] [Related]
17. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation.
Tremblay AM; Missiaglia E; Galli GG; Hettmer S; Urcia R; Carrara M; Judson RN; Thway K; Nadal G; Selfe JL; Murray G; Calogero RA; De Bari C; Zammit PS; Delorenzi M; Wagers AJ; Shipley J; Wackerhage H; Camargo FD
Cancer Cell; 2014 Aug; 26(2):273-87. PubMed ID: 25087979
[TBL] [Abstract][Full Text] [Related]
18. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
19. 12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells.
Marchesi I; Sanna L; Fais M; Fiorentino FP; Giordano A; Bagella L
J Cell Physiol; 2018 Mar; 233(3):2360-2365. PubMed ID: 28722764
[TBL] [Abstract][Full Text] [Related]
20. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C
Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
